Hiroto Inaba1,2, Xueyuan Cao3,4, Alice Q Han1, John C Panetta5, Kirsten K Ness6, Monika L Metzger1,2, Jeffrey E Rubnitz1,2, Raul C Ribeiro1,2, John T Sandlund1,2, Sima Jeha1,2, Cheng Cheng3, Ching-Hon Pui1,2, Mary V Relling5,7, Sue C Kaste8,9. 1. Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 2. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee. 3. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Acute and Tertiary Care, University of Tennessee Health Science Center, Memphis, Tennessee. 5. Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee. 6. Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee. 7. Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee. 8. Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee. 9. Department of Radiology, University of Tennessee Health Science Center, Memphis, Tennessee.
Abstract
BACKGROUND: Children with acute lymphoblastic leukemia (ALL) can develop reduced bone mineral density (BMD). However, data from patients who received treatment on a frontline regimen without cranial irradiation are limited, and no genome-wide analysis has been reported. METHODS: Lumbar BMD was evaluated by quantitative computed tomography at diagnosis, after 120 weeks of continuation therapy, and after 2 years off therapy in pediatric patients with ALL (ages 2-18 years at diagnosis) who were treated on the St. Jude Total XV Protocol. Clinical, pharmacokinetic, and genetic risk factors associated with decreased BMD Z-scores were evaluated. RESULTS: The median BMD Z-score in 363 patients was 0.06 at diagnosis, declined to -1.08 at week 120, but partly recovered to -0.72 after 2 years off therapy; BMD in patients with low BMD Z-scores at diagnosis remained low after therapy. Older age (≥10 years vs 2-9.9 years at diagnosis; P < .001), a higher BMD Z-score at diagnosis (P = .001), and a greater area under the plasma drug concentration-time curve for dexamethasone in weeks 7 and 8 of continuation therapy (P = .001) were associated with a greater decrease in BMD Z-score from diagnosis to week 120. Single-nucleotide polymorphisms in 2 genes important in osteogenesis and bone mineralization (COL11A1 [reference single-nucleotide polymorphism rs2622849]; P = 2.39 × 10-7 ] and NELL1 [rs11025915]; P = 4.07 × 10-6 ]) were associated with a decreased BMD Z-score. NELL1 (P = .003) also was associated with a greater dexamethasone area under the plasma drug concentration-time curve. CONCLUSIONS: BMD Z-scores decreased during therapy, especially in patients who had clinical, pharmacokinetic, and genetic risk factors. Early recognition of BMD changes and strategies to optimize bone health are essential. Cancer 2018;124:1025-35.
BACKGROUND:Children with acute lymphoblastic leukemia (ALL) can develop reduced bone mineral density (BMD). However, data from patients who received treatment on a frontline regimen without cranial irradiation are limited, and no genome-wide analysis has been reported. METHODS: Lumbar BMD was evaluated by quantitative computed tomography at diagnosis, after 120 weeks of continuation therapy, and after 2 years off therapy in pediatric patients with ALL (ages 2-18 years at diagnosis) who were treated on the St. Jude Total XV Protocol. Clinical, pharmacokinetic, and genetic risk factors associated with decreased BMD Z-scores were evaluated. RESULTS: The median BMD Z-score in 363 patients was 0.06 at diagnosis, declined to -1.08 at week 120, but partly recovered to -0.72 after 2 years off therapy; BMD in patients with low BMD Z-scores at diagnosis remained low after therapy. Older age (≥10 years vs 2-9.9 years at diagnosis; P < .001), a higher BMD Z-score at diagnosis (P = .001), and a greater area under the plasma drug concentration-time curve for dexamethasone in weeks 7 and 8 of continuation therapy (P = .001) were associated with a greater decrease in BMD Z-score from diagnosis to week 120. Single-nucleotide polymorphisms in 2 genes important in osteogenesis and bone mineralization (COL11A1 [reference single-nucleotide polymorphism rs2622849]; P = 2.39 × 10-7 ] and NELL1 [rs11025915]; P = 4.07 × 10-6 ]) were associated with a decreased BMD Z-score. NELL1 (P = .003) also was associated with a greater dexamethasone area under the plasma drug concentration-time curve. CONCLUSIONS: BMD Z-scores decreased during therapy, especially in patients who had clinical, pharmacokinetic, and genetic risk factors. Early recognition of BMD changes and strategies to optimize bone health are essential. Cancer 2018;124:1025-35.
Authors: Torben S Mikkelsen; Alex Sparreboom; Cheng Cheng; Yinmei Zhou; James M Boyett; Susana C Raimondi; John C Panetta; W Paul Bowman; John T Sandlund; Ching-Hon Pui; Mary V Relling; William E Evans Journal: J Clin Oncol Date: 2011-03-28 Impact factor: 44.544
Authors: Aaron W James; Jia Shen; Xinli Zhang; Greg Asatrian; Raghav Goyal; Jin H Kwak; Lin Jiang; Benjamin Bengs; Cymbeline T Culiat; A Simon Turner; Howard B Seim Iii; Benjamin M Wu; Karen Lyons; John S Adams; Kang Ting; Chia Soo Journal: Nat Commun Date: 2015-06-17 Impact factor: 14.919
Authors: Anna Petryk; Lynda E Polgreen; Molly Grames; Dawn A Lowe; James S Hodges; Peter Karachunski Journal: Muscle Nerve Date: 2017-02-06 Impact factor: 3.217
Authors: Hiroto Inaba; Xueyuan Cao; Jennifer Y Chang; Seth E Karol; John C Panetta; Kirsten K Ness; Cheng Cheng; Ching-Hon Pui; Mary V Relling; Sue C Kaste Journal: Br J Haematol Date: 2020-03-24 Impact factor: 6.998
Authors: Carolina Simioni; Giorgio Zauli; Alberto M Martelli; Marco Vitale; Simona Ultimo; Daniela Milani; Luca M Neri Journal: Oncotarget Date: 2018-03-30
Authors: Jenneke E van Atteveld; Demi Tc de Winter; Rob Pieters; Sebastian Jcmm Neggers; Marry M van den Heuvel-Eibrink Journal: Fac Rev Date: 2021-06-23